(Taken from Wikipedia)
Bevacizumab (trade name Avastin, Genentech/Roche) is a monoclonal antibody agent that has specific reactivity against vascular endothelial growth factor-A (VEGF-A). It is used in the treatment of cancer, where it inhibits tumor growth by blocking the formation of new blood vessels (angiogenesis). Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.
Bevacizumab is currently approved by the U.S. Food and Drug Administration for cancers that are metastatic (have spread to other parts of the body). It received its first approval in 2004 was for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer. In 2008, it was approved by the FDA for use in metastatic breast cancer, a decision that generated some controversy as it went against the recommendation of its advisory panel, who objected because it only slowed tumor growth but failed to extend survival.
Clinical studies are underway in non-metastatic colon cancer, non-metastatic breast cancer, renal cell carcinoma, glioblastoma multiform (GBM), ovarian cancer, hormone-refractory prostate cancer, non-metastatic unresectable liver cancer and metastatic or unresectable locally advanced pancreatic cancer.
Bevacizumab (trade name Avastin, Genentech/Roche) is a monoclonal antibody agent that has specific reactivity against vascular endothelial growth factor-A (VEGF-A). It is used in the treatment of cancer, where it inhibits tumor growth by blocking the formation of new blood vessels (angiogenesis). Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.
Bevacizumab is currently approved by the U.S. Food and Drug Administration for cancers that are metastatic (have spread to other parts of the body). It received its first approval in 2004 was for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer. In 2008, it was approved by the FDA for use in metastatic breast cancer, a decision that generated some controversy as it went against the recommendation of its advisory panel, who objected because it only slowed tumor growth but failed to extend survival.
Clinical studies are underway in non-metastatic colon cancer, non-metastatic breast cancer, renal cell carcinoma, glioblastoma multiform (GBM), ovarian cancer, hormone-refractory prostate cancer, non-metastatic unresectable liver cancer and metastatic or unresectable locally advanced pancreatic cancer.
PS: I am currently scheduled to received my first Avastin infusion around March 5th. I'll keep you all posted on the exact schedule.
No comments:
Post a Comment